The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The prevalence of germline mutations among patients with solid tumors with genomic alterations identified on tumor testing: Results from a tertiary care academic center molecular tumor board.
 
Catherine Watson
No Relationships to Disclose
 
Sarah Tait
No Relationships to Disclose
 
Lindsay Soo
No Relationships to Disclose
 
Jennifer Kay Plichta
Research Funding - Color Genomics
 
Tian Zhang
Leadership - Capio BioSciences (I)
Stock and Other Ownership Interests - Archimmune Therapeutics (I); Capio Biosciences (I)
Honoraria - Exelixis; Genentech/Roche; MJH Life Sciences
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Exelixis; Foundation Medicine; Genentech/Roche; Janssen; Merck; Pfizer; Pharmacyclics; Sanofi; Seagen
Speakers' Bureau - Exelixis; Genentech/Roche; Genomic Health; Sanofi/Aventis
Research Funding - Acerta Pharma (Inst); Janssen (Inst); Merck (Inst); Merrimack (Inst); Mirati Therapeutics (Inst); Novartis (Inst); OmniSeq (Inst); Personal Genome Diagnostics (Inst); Pfizer (Inst); Regeneron (Inst); Stem CentRx (Inst)
Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture by c-MET technology (Inst); Prochelators as Targeted Prodrugs for Prostate Cancer (Inst)
Travel, Accommodations, Expenses - Acerta Pharma; AstraZeneca; Genomic Health
 
Edgardo Castellar
Consulting or Advisory Role - Almac Diagnostics
 
Andrew J. Armstrong
Honoraria - Dendreon; Janssen Oncology
Consulting or Advisory Role - Astellas Scientific and Medical Affairs Inc; AstraZeneca; Bayer; Clovis Oncology; Dendreon; Janssen Biotech; Medivation; Pfizer; Sanofi
Speakers' Bureau - Bayer; Dendreon
Research Funding - Active Biotech (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); Gilead Sciences (Inst); Janssen Oncology (Inst); Medivation (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture technology (Inst)
Travel, Accommodations, Expenses - Astellas Scientific and Medical Affairs Inc; Bayer; Dendreon; Janssen Biotech
 
Rebecca A. Previs
Research Funding - Myriad Pharmaceuticals
 
John H. Strickler
Consulting or Advisory Role - Amgen; Bayer; Chengdu Kanghong Biotech; Genentech/Roche; OncoMed; Proteus Digital Health; Seagen
Research Funding - Abbvie (Inst); Amgen (Inst); Curegenix; Exelixis (Inst); Gilead Sciences (Inst); Leap Therapeutics (Inst); Macrogenics (Inst); MedImmune (Inst); Nektar (Inst); Roche/Genentech (Inst); Seagen (Inst)
 
Michelle Green
Employment - N-of-One
 
Michael Datto
No Relationships to Disclose
 
Paul Kelly Marcom
Consulting or Advisory Role - Celltrion; Genentech/Roche; Immunomedics; Merck; Novartis
Speakers' Bureau - Catamount Medical Education; Clinical Care Options
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Genentech/Roche (Inst); Glycomimetics (Inst); Innocrin Pharma (Inst); Novartis (Inst); Verily (Inst)
 
Carolyn S. Menendez
No Relationships to Disclose